$14.43+0.02 (+0.14%)
BrainsWay Ltd.
BrainsWay Ltd. in the Healthcare sector is trading at $14.43 with a market capitalization of $563M. Wall Street consensus targets $16.67 (3 analysts), implying a +15.5% move over the next 12 months. The stock is currently 17% below its 52-week high of $17.35, remaining 30.2% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of majo...
As hopes for a U.S.-Iran peace deal buoy investor sentiment, most Gulf markets have seen gains, with Dubai's main share index rising by 1.1% and Abu Dhabi's index up by 0.5%. In this context of easing geopolitical tensions and improved risk appetite, identifying promising stocks involves looking for those that can capitalize on regional stability and economic growth prospects.
BrainsWay Ltd (BRSYF) reports a 35% revenue increase and strategic advancements in mental health solutions, despite rising expenses and market uncertainties.
Brainsway (NASDAQ:BWAY) reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its recurring revenue base. Chief Executive Officer Hadar Levy said on the company’s earnings call that rev
BrainsWay (NASDAQ:BWAY) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://viavid.webcasts.com/starthere.jsp?ei=1760244&tp_key=9c697b1af2 Summary Brainsway Ltd reported a 35% increase in revenue for Q1 2026, reaching $15.5 million, driven b
Here is how Brainsway Ltd. Sponsored ADR (BWAY) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.